Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone for Radiation-Induced Fibrosis
NCT00020631Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in radiation fibrosis syndrome (RIF), sponsored by National Cancer Institute. Primary endpoints: Safety and Adverse Events up to 2 years and Principal Functional Abilities. Started Oct 2001; status: completed.
02
Drugs
pirfenidone
03
Conditions
radiation fibrosis syndrome (RIF)
Beyond the preview
Go deeper on NCT00020631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00020631.